Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Y-mAbs Therapeutics (YMAB) Tops Q1 EPS by 8c

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

May 9, 2022 4:01 PM EDT

Completed resubmission to the FDA of omburtamab BLADANYELZA® adoption drove a 9% sequential revenue increase to $10.5 millionCompany issues 2022 full-year DANYELZA® revenue guidance of $45-$50 millionStrong cash position with $156.7 million as of March 31, 2022, providing runway through mid-2024 The Company will host a conference call on Tuesday, May 10, 2022, at 9 a.m. ET

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based... More